Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future OncologyPRNewsWire • 04/19/21
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer SettingsBenzinga • 04/06/21
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's LymphomaPRNewsWire • 04/06/21
Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood CancerBenzinga • 03/29/21
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple MyelomaPRNewsWire • 03/29/21
Expanded Partnership with Medidata Supports Karyopharm's Mission to Develop First-in-Class TherapeuticsBusiness Wire • 03/10/21
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPAPRNewsWire • 02/24/21
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/11/21
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell LymphomaPRNewsWire • 02/04/21
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple MyelomaPRNewsWire • 01/29/21
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior TherapyPRNewsWire • 12/21/20
KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTIBusiness Wire • 12/19/20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior TherapyPRNewsWire • 12/18/20
Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 12/15/20
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple MyelomaPRNewsWire • 12/11/20
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/07/20
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/07/20
Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual MeetingPRNewsWire • 12/01/20
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any ModificationPRNewsWire • 11/25/20
